Trial Profile

A Phase II Open-Label Study of UM171-Expanded Cord Blood Transplantation in Patients With High and Very High Risk Acute Leukemia/Myelodysplasia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allogeneic umbilical cord-derived CD34-cells unexpanded/dorocubicel (Primary) ; Cyclophosphamide; Fludarabine; MMF; Tacrolimus; Thiotepa
Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors ExCellThera

Most Recent Events

23 Mar 2026 Status changed from active, no longer recruiting to completed.
10 Mar 2026 Results presented in the ExCellThera Media Release.
10 Mar 2026 According to an ExCellThera media release, Topline results will be presented on March 23, 2026 at the 52nd EBMT Annual Meeting in Madrid, Spain.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com